Navigation Links
Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
Date:1/6/2014

SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the J.P. Morgan 2014 Healthcare Conference in San Francisco. The presentation is scheduled for Tuesday, January 14 at 11:30 a.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®. Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for Contrave is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company has submitted applications for marketing authorization in the United States and Europe, with potential approvals in 2014. If approved, North American partner Takeda Pharmaceuticals will commercialize Contrave in the United States. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com. Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
2. Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
3. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
4. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
7. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
8. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
9. Orexigen Therapeutics to Present at Upcoming Conferences
10. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
11. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 Lyme Research ... of Lyme disease research at universities, today announced the ... on the identification, treatment and cure for Lyme and ... received the most applications in its history—over 20 grant ... “While we were pleased to receive so many solid ...
(Date:9/30/2014)... September 30, 2014 On September 11, Pharma ... Sherley in anticipation of a session that he will lead ... Summit,” scheduled for February 17-18, 2015 in London. In ... IQ asked Dr. Sherley to respond to several questions on ... challenges to evaluating stem cell toxicity, and future trends in ...
(Date:9/30/2014)... Ontario, Canada (PRWEB) September 30, 2014 Back ... based on 500 square feet. per employee, which included space ... world back then.” says Jeff Howell, partner at Nidea ... advisory firm in Toronto. “By the year 2000, however, ... are now seeing that number come down to 175 to ...
(Date:9/29/2014)... at the forefront of diagnostics today, with imaging ... tomography), scanning, and NMR (nuclear magnetic resonance) increasing ... problems of image resolution and quality still limit ... tissue. A solution is hyperpolarization, which involves injecting ... quality by following the distribution and fate of ...
Breaking Biology Technology:Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3
... 2011 Clinicians now have a new tool to help ... -- one of the most common sexually transmitted infections in ... BD (Becton, Dickinson and Company), announced today that it received ... first fully automated molecular tests to detect and differentiate HSV ...
... 2011 The Japanese nuclear crisis has caused a ... not only in Japan, but as far away as ... iodide does not provide generalized radiation protection because it ... bombarded with orders as the radiation hysteria mounts. ...
... (Nasdaq: VRML ) – Vermillion, a molecular ... coverage March 23, 2011 on Vermillion. This ... at Stephens by contacting, Scott Gleason at scott.gleason@stephens.com ... Vermillion, Inc. is dedicated to the discovery, development and ...
Cached Biology Technology:BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens 2Shortages of Potassium Iodide as Radiation Panic Drives Demand 2Stephens Initiates Coverage on Vermillion 2Stephens Initiates Coverage on Vermillion 3
(Date:9/30/2014)... you want your doctor to know what goes wrong with ... good idea to know what "normal" actually is. That,s where ... of the FASEB Journal comes in. ... transcriptomea key set of molecules that can help scientists "see" ... time. What,s more, they found never-before-detected gene activity and that ...
(Date:9/30/2014)... threats in today,s ocean. From overfishing and pollution ... ecosystems are disappearing at unprecedented rates around the ... surrounding the island of Moorea in French Polynesia ... coral guard-crabs. New research from the National Museum ... McKeon and the museum,s predoctoral fellow Jenna Moore ...
(Date:9/29/2014)... that the exposure to tar tended to be lower ... Similarly, exposure to nicotine tended to be lower. ... cigarette in several countries around the world. Previous studies ... in the smoke of these cigarettes are lower than ... chemicals in the smoke are not necessarily linked to ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Slim cigarette smokers not exposed to more harmful chemicals 2
... of Salamanca and another from Yale University have shown that ... beershebensis , a lizard species from the Negev Desert in ... less and catch less mobile and different prey if they ... predicted this result, but until now there had been very ...
... National Primate Research Center, Emory University, have successfully ... step toward unlocking the genetic secrets of pair ... will enable scientists to perform a host of ... mechanisms of social bonding and other complex social ...
... is available in German . , Brown adipose ... mitochondria, miniature power stations which among other things can ,burn, ... that of a battery, which then provides energy for cellular processes. ... They go full steam ahead all the time. The energy released ...
Cached Biology News:Lizards change their diet to avoid predators 2Yerkes researchers create first transgenic prairie voles 2Brown fat cells make 'spare tires' shrink 2
... Motic's B3 series of microscopes offer ... microscope required for laboratory work. Equipped with ... Super Contrast (ASC) objectives. The B3 is ... The Siedentopf binocular tube eliminates the need ...
... SYBR Green II RNA gel ... gel stain that has bright fluorescence when ... gels, making it ideal for use with ... scanners or standard UV transilluminators. A 500 ...
... SYBR Green II RNA gel stain ... has bright fluorescence when bound to RNA and ... use with either formaldehyde/agarose or polyacrylamide gels using ... stains 100 minigels. A 500 µL unit size ...
... Glutathion-S-transferases (GST) are a group ... the detoxification processes. The GSTs are ... Pi, Teta and microsomal. The classes ... and s Sample Size: ...
Biology Products: